New combo aims to stop liver cancer from coming back after surgery

NCT ID NCT06467799

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether giving chemotherapy directly into the liver artery plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from returning in high-risk patients. The study enrolls 39 adults with hepatocellular carcinoma beyond Milan criteria. The main goal is to see how many patients remain cancer-free one year after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (an immunotherapy drug) and FOLFOX chemotherapy given directly into the liver artery
What this could lead to: If successful, this approach could reduce the chance of liver cancer returning after surgery, potentially improving long-term survival for high-risk patients.
What could go wrong: This is a small, early-phase trial with only 39 participants and no comparison group, so results may not apply broadly. The combination therapy also carries risks of side effects from both chemotherapy and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEYOND MILAN CRITERIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BEYOND MILAN CRITERIA HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.